Wednesday’s trading has closed, but MYL is being traded in the after-hours session.
After-Hours quote »| 31.27 Data as of 4:00pm ET |  -0.60 / -1.88%Today’s Change | 20.50 Today|||52-Week Range 32.27 | +13.92% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Generic | MARKET CAP $12.1B |
Company Description
Mylan, Inc. is a generic and specialty pharmaceuticals company, through its subsidiaries, which develops, manufactures, markets and distributes pharmaceuticals. The company operates its business through two segments: Generics & Specialty. The Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages mainly in the development, manufacture and sale of branded specialty nebulized and injectable products. Mylan was founded by Milan Puskar and Don Panoz in 1961 and is headquartered in Canonsburg, PA.
Employees
Shareholders
| Other institutional | 52.03% |
| Mutual fund holders | 39.07% |
| Individual stakeholders | 2.44% |
Top Executives
| Heather M. Bresch, MBA | Chief Executive Officer & Director |
| Rajiv Malik, MBA | President & Director |
| Harry A. Korman | Chief Operating Officer & Executive Vice President |
| John D. Sheehan, CPA | Chief Financial Officer & Executive Vice President |
| Bryan G. Byala, MBA | Treasurer & Senior Vice President |
.
